Intellectus Partners LLC Has $732,000 Stock Holdings in Cencora, Inc. (NYSE:COR)

Intellectus Partners LLC grew its holdings in Cencora, Inc. (NYSE:COR) by 6.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,260 shares of the company’s stock after purchasing an additional 202 shares during the quarter. Intellectus Partners LLC’s holdings in Cencora were worth $732,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. AMF Tjanstepension AB lifted its stake in shares of Cencora by 147.4% in the 4th quarter. AMF Tjanstepension AB now owns 79,207 shares of the company’s stock valued at $17,799,000 after purchasing an additional 47,193 shares during the period. Banco Santander S.A. bought a new stake in Cencora in the 4th quarter valued at about $821,000. Haven Private LLC bought a new stake in Cencora in the 4th quarter valued at about $753,000. Novus Advisors LLC bought a new stake in Cencora in the 4th quarter valued at about $225,000. Finally, Edgestream Partners L.P. increased its position in Cencora by 585.7% in the 4th quarter. Edgestream Partners L.P. now owns 19,734 shares of the company’s stock valued at $4,434,000 after buying an additional 16,856 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,648 shares of company stock valued at $2,862,342 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $254.54 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a 50 day moving average price of $244.34 and a two-hundred day moving average price of $238.40. The firm has a market capitalization of $49.36 billion, a P/E ratio of 36.21, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $262.26.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on COR. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. StockNews.com lowered Cencora from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company boosted their target price on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.